NCT03686124 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03686124
Title	ACTengine IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (ACTengine)
Acronym	ACTengine
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	Immatics US, Inc.
Indications	Advanced Solid Tumor lung cancer fallopian tube cancer peritoneum cancer head and neck cancer ovary serous adenocarcinoma triple-receptor negative breast cancer endometrioid ovary carcinoma endometrial carcinoma uveal melanoma
Therapies	IMA-203
Age Groups:	adult \| senior
Covered Countries	USA \| DEU

NCT03686124
Clinical Trial Detail